Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Yes. The U.S. Food and Drug Administration reportedly rejected Neuralink’s application to begin human clinical testing in 2022. Reuters, citing seven current and former employees, said the agency returned the application with dozens of issues, including major safety questions about the implant. The FDA’s confidential rejection letter has not been released, so the detailed deficiencies remain reported rather than independently documented.
The rejection was not a final decision that Neuralink could never test people, and it was not a commercial-approval ruling. Neuralink later announced that the FDA had authorized its first-in-human study in May 2023. That authorization allowed an investigation under tightly controlled clinical conditions; it did not make the brain implant an approved consumer product.
As an Amazon Associate I earn from qualifying purchases.
What exactly did the FDA reject?
Neuralink sought permission in early 2022 to start clinical testing of its brain-computer interface in people. According to Reuters’ March 2–3, 2023 reporting, the FDA rejected the submission and sent the company a list of dozens of problems that had to be addressed.
The reported decision concerned permission to conduct a human study. It was not a marketing-approval decision for selling Neuralink’s implant, and it did not establish that the technology was permanently barred from clinical research. Because the FDA’s letter is confidential, the public cannot independently check the complete list of deficiencies or the agency’s exact wording.
#1 Best Overall
Which safety concerns were reported?
Reuters’ sources described three central areas of concern. These points should be attributed to that employee reporting, not presented as a publicly released FDA finding.
The implant’s lithium battery
A lithium battery is part of the implanted system. Regulators were reportedly concerned about how the battery would behave inside the body, including the consequences of a failure or other complication. The available reporting does not publish the FDA’s technical risk analysis or a definitive finding that the battery was unsafe.
Rank #2
Electrode wires moving in the brain
The N1 system uses very fine electrode threads placed in brain tissue. Reported questions included whether those wires could migrate after surgery and what that movement could mean for performance, injury risk or future procedures. The full specifications and the FDA’s requested corrective work were not made public.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Removing the implant without damaging tissue
Employees also told Reuters that the agency questioned whether the device could be removed safely. Any removal would have to account for the threads’ position in delicate brain tissue, as well as the implant and surgical hardware. Public reports do not provide a complete removal protocol or confirm how each concern was resolved.
Neuralink’s regulatory timeline
| Date | Event | What it means |
|---|---|---|
| 2016 | Neuralink was founded, according to the Reuters-sourced account. | The company began developing its implant and surgical system. |
| Early 2022 | Neuralink sought FDA permission for human trials. | The application was reportedly rejected and returned with dozens of issues. |
| March 2–3, 2023 | Reuters made the reported rejection public. | The confidential FDA letter itself remained unavailable. |
| May 2023 | Neuralink announced FDA authorization for a first-in-human clinical study. | The company said it had cleared the regulatory step needed to begin an investigational trial. |
| January 2024 | Reporting described the first human implant. | The device had moved into early clinical investigation, not general medical or consumer use. |
What does FDA authorization for the study mean?
The relevant FDA mechanism is an investigational device exemption (IDE). The FDA defines an IDE as permission for an investigational device to be used in a clinical study to collect safety and effectiveness data.
For a significant-risk device, FDA approval of the IDE is generally required along with approval from an institutional review board. The study must include protections for human participants and follow the approved protocol.
An IDE therefore permits research use under specified conditions. It does not mean the device has been cleared or approved for routine treatment, sold to the public, or proven safe and effective. Neuralink’s PRIME materials describe the N1 implant and its surgical system as investigational medical devices in a first brain-computer-interface clinical trial.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What happened after the reported rejection?
Neuralink continued working through the FDA process and announced the May 2023 authorization. The later authorization shows that the earlier setback was eventually addressed well enough for a study to proceed, but it does not reveal which changes the company made or whether every reported concern was resolved in the same way.
Best Value
Neuralink’s announcement is the basis for the public claim that the study was authorized. It should not be expanded into a claim that the FDA publicly endorsed every technical detail of the program. The subsequent human implant described in January 2024 reporting was part of that investigational pathway.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is Neuralink approved, or is it still experimental?
| Regulatory status | What it allows | Neuralink’s reported position |
|---|---|---|
| Preclinical development | Laboratory and animal work before human testing. | The stage before the company’s human-trial authorization. |
| IDE-authorized clinical investigation | Use of an investigational device in an approved study to gather safety and effectiveness data. | The stage Neuralink announced in May 2023 for its first-in-human study. |
| Marketing clearance or approval | Commercial distribution for a defined intended use after the applicable FDA review. | Not established by the reported IDE authorization; the N1 implant remains investigational in the PRIME materials. |
In practical terms, Neuralink’s human-trial authorization is a research milestone, not a declaration that the implant is ready for ordinary patients or consumers. People should also avoid treating external EEG headsets or other consumer neurotechnology as equivalent substitutes: they differ in invasiveness, signal collection, intended users, evidence and regulatory status.
What remains unknown?
- The FDA’s rejection letter and complete deficiency list have not been publicly released in the cited reporting.
- The public record does not give a complete technical explanation of the battery, wire-migration or removal concerns.
- Neuralink’s announcement of authorization does not independently document every study detail or the outcome of each requested change.
- Early human implantation does not by itself establish long-term safety, effectiveness or commercial approval.
The accurate summary is therefore narrow: Neuralink’s reported 2022 application to test its brain implant in humans was rejected after regulators raised substantial safety questions, and the company later announced FDA authorization to begin an investigational first-in-human study in May 2023. The device remains an experimental clinical technology rather than an approved consumer product.
Free tools Windows power users keep installed
One-click scans. No signup required.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
